Cardionomic’s investors are positioned to achieve significant rewards.
The Cardionomic team has demonstrated high levels of capital efficiency in developing this breakthrough therapy and expects to demonstrate similar success moving forward.
Cardionomic successfully completed a $20M Series A Round funding in October of 2015.
The company’s primary patents have been issued (8,798,738; 8,818,501; 8,818,501; 8,798,738; 9,480,790; 9,878,150
7,532,938; 7,865,237; 11201608878S; 3,194,007B1.) Cardionomic continues to develop an extensive portfolio covering all aspects of the system.
CAUTION: INVESTIGATIONAL DEVICE LIMITED BY FEDERAL (UNITED STATES) LAW TO INVESTIGATIONAL USE.
©2021 Cardionomic, Inc. All Rights Reserved.